deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03181126

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Sponsor: AbbVie

Conditions Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma
Interventions Chemotherapy Navitoclax Venetoclax
Updated 24 times since 2017 Last updated: Oct 7, 2021 Started: Nov 27, 2017 Primary completion: Nov 11, 2020 Completion: Nov 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma, this trial is completed. The trial is conducted by AbbVie and has accumulated 24 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Nov 2021 · 9 months · monthly snapshot~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Feb 2021 — Nov 2021 [monthly]

    Completed PHASE1

▶ Show 19 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Oct 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  5. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  6. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  7. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  8. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  9. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  10. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  11. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  12. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  14. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  15. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1

  16. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  17. Nov 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE1

  18. Oct 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE1

  19. Jun 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chapel Hill, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Duarte, United States , Houston, United States , Madison, United States , Melbourne, Australia , Memphis, United States and 3 more locations